Details of the Drug

General Information of Drug (ID: DM2QHZU)

Drug Name

Sulindac

Synonyms

Aclin; Aflodac; Arthrobid; Arthrocine; Chibret; Clinoril; Copal; Copals; Kenalin; Klinoril; Mobilin; Sulindaco; Sulindacum; Sulindal; Alphapharm Brand of Sulindac; Apo Sulin; Apotex Brand of Sulindac; Cahill May Roberts Brand of Sulindac; Chemia Brand of Sulindac; Copal resin; Copal rosin varnish; Gum copal; KendrickBrand of Sulindac; Merck Brand of Sulindac; Novo Sundac; Novopharm Brand of Sulindac; Nu Pharm Brand of Sulindac; Nu Sulindac; Resin copal; Sulindac sulfoxide; MK 231; MK231; S 8139; Apo-Sulin; Clinoril (TN); MK-231; Merck Sharp & Dohme Brand of Sulindac; Novo-Sundac; Nu-Pharm Brand of Sulindac; Nu-Sulindac; Sulindaco [INN-Spanish]; Sulindacum [INN-Latin]; Sulindac (JAN/USP/INN); Sulindac [USAN:BAN:INN:JAN]; Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid; Cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; {5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid; Cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; [(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid; {(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; (E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Approved	[1], [2]

Therapeutic Class

Antiinflammatory Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

356.4

Topological Polar Surface Area (xlogp)

3.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The absorption of drug is approximately 90% following oral administration [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability: 88% of drug becomes completely available to its intended biological destination(s) [5]
Clearance: The renal clearance of drug is 68.12 +/- 27.56 mL/min [6]
Elimination: 1% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 7.8 hours [7]
Metabolism: The drug is metabolized via the hepatic [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 16.0325 micromolar/kg/day [8]
Water Solubility: The ability of drug to dissolve in water is measured as 0.0028 mg/mL [4]

Chemical Identifiers

Formula: C20H17FO3S
IUPAC Name: 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
Canonical SMILES: CC\\1=C(C2=C(/C1=C\\C3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O
InChI: InChI=1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
InChIKey: MLKXDPUZXIRXEP-MFOYZWKCSA-N

Cross-matching ID

PubChem CID: 1548887
ChEBI ID: CHEBI:9352
CAS Number: 38194-50-2
DrugBank ID: DB00605
TTD ID: D0Z5IU
VARIDT ID: DR00715
ACDINA ID: D00644

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aldose reductase (AKR1B1)	TTFBNVI	ALDR_HUMAN	Inhibitor	[9], [10]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 4 (ABCC4)	DTCSGPB	MRP4_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Rheumatoid arthritis

ICD Disease Classification

FA20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Aldose reductase (AKR1B1)	DTT	AKR1B1	1.08E-20	0.94	1.58
Multidrug resistance-associated protein 4 (ABCC4)	DTP	MRP4	4.80E-02	-2.04E-02	-2.13E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Sulindac

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Sulfasalazine	DMICA9H	Moderate	Increased risk of nephrotoxicity by the combination of Sulindac and Sulfasalazine.	Rheumatoid arthritis [FA20]	[29]
Dexamethasone	DMMWZET	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Dexamethasone.	Rheumatoid arthritis [FA20]	[30]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Sulindac and Leflunomide.	Rheumatoid arthritis [FA20]	[31]
-----------

Coadministration of a Drug Treating the Disease Different from Sulindac (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Sulindac and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[32]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Sulindac and Repaglinide.	Acute diabete complication [5A2Y]	[33]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Sulindac and Glibenclamide.	Acute diabete complication [5A2Y]	[33]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Sulindac and Tolazamide.	Acute diabete complication [5A2Y]	[33]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Sulindac and Nateglinide.	Acute diabete complication [5A2Y]	[33]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Sulindac and Glipizide.	Acute diabete complication [5A2Y]	[33]
Inotersen	DMJ93CT	Major	Increased risk of bleeding by the combination of Sulindac and Inotersen.	Amyloidosis [5D00]	[34]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Sulindac and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[35]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Sulindac and Cilostazol.	Arterial occlusive disease [BD40]	[36]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Budesonide.	Asthma [CA23]	[30]
Ofloxacin	DM0VQN3	Moderate	Additive CNS stimulant effects by the combination of Sulindac and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[37]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Sulindac and Kanamycin.	Bacterial infection [1A00-1C4Z]	[38]
Trovafloxacin	DM6AN32	Moderate	Additive CNS stimulant effects by the combination of Sulindac and Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[37]
Sparfloxacin	DMB4HCT	Moderate	Additive CNS stimulant effects by the combination of Sulindac and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[37]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Sulindac and Streptomycin.	Bacterial infection [1A00-1C4Z]	[38]
Gemifloxacin	DMHT34O	Moderate	Additive CNS depression effects by the combination of Sulindac and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[37]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS stimulant effects by the combination of Sulindac and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[37]
ABT-492	DMJFD2I	Moderate	Additive CNS depression effects by the combination of Sulindac and ABT-492.	Bacterial infection [1A00-1C4Z]	[37]
Gentamicin	DMKINJO	Moderate	Increased risk of nephrotoxicity by the combination of Sulindac and Gentamicin.	Bacterial infection [1A00-1C4Z]	[38]
Netilmicin	DMRD1QK	Moderate	Increased risk of nephrotoxicity by the combination of Sulindac and Netilmicin.	Bacterial infection [1A00-1C4Z]	[38]
Levofloxacin	DMS60RB	Moderate	Additive CNS stimulant effects by the combination of Sulindac and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[37]
Tobramycin	DMUI0CH	Moderate	Increased risk of nephrotoxicity by the combination of Sulindac and Tobramycin.	Bacterial infection [1A00-1C4Z]	[38]
Lomefloxacin	DMVRH9C	Moderate	Additive CNS stimulant effects by the combination of Sulindac and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[37]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Etidronic acid.	Bone paget disease [FB85]	[39]
Risedronate	DM5FLTY	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Risedronate.	Bone paget disease [FB85]	[39]
Alendronate	DMY2KX9	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Alendronate.	Bone paget disease [FB85]	[39]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Sulindac and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[40]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of bleeding by the combination of Sulindac and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[36]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Sulindac and Iodipamide.	Cholelithiasis [DC11]	[41]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Sulindac and Levomilnacipran.	Chronic pain [MG30]	[42]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Sulindac and Regorafenib.	Colorectal cancer [2B91]	[34]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Sulindac and Drospirenone.	Contraceptive management [QA21]	[43]
Methoxyflurane	DML0RAE	Moderate	Increased risk of nephrotoxicity by the combination of Sulindac and Methoxyflurane.	Corneal disease [9A76-9A78]	[34]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Sulindac and Ardeparin.	Coronary thrombosis [BA43]	[44]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Sulindac and Danaparoid.	Deep vein thrombosis [BD71]	[44]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Sulindac and Rivaroxaban.	Deep vein thrombosis [BD71]	[45]
Sertraline	DM0FB1J	Moderate	Increased risk of bleeding by the combination of Sulindac and Sertraline.	Depression [6A70-6A7Z]	[42]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Sulindac and Vilazodone.	Depression [6A70-6A7Z]	[42]
Paroxetine	DM5PVQE	Moderate	Increased risk of bleeding by the combination of Sulindac and Paroxetine.	Depression [6A70-6A7Z]	[42]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Sulindac and Vortioxetine.	Depression [6A70-6A7Z]	[42]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Sulindac and Milnacipran.	Depression [6A70-6A7Z]	[42]
Escitalopram	DMFK9HG	Moderate	Increased risk of bleeding by the combination of Sulindac and Escitalopram.	Depression [6A70-6A7Z]	[42]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Sulindac and Desvenlafaxine.	Depression [6A70-6A7Z]	[42]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Sulindac and Clomipramine.	Depression [6A70-6A7Z]	[42]
PMID28870136-Compound-49	DMTUC9E	Moderate	Increased risk of bleeding by the combination of Sulindac and PMID28870136-Compound-49.	Discovery agent [N.A.]	[46]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Sulindac and Cannabidiol.	Epileptic encephalopathy [8A62]	[34]
Ethacrynic acid	DM60QMR	Moderate	Antagonize the effect of Sulindac when combined with Ethacrynic acid.	Essential hypertension [BA00]	[47]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Sulindac and Tazemetostat.	Follicular lymphoma [2A80]	[36]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Sulindac and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[34]
Sulfinpyrazone	DMEV954	Moderate	Increased risk of bleeding by the combination of Sulindac and Sulfinpyrazone.	Gout [FA25]	[36]
Eplerenone	DMF0NQR	Moderate	Antagonize the effect of Sulindac when combined with Eplerenone.	Heart failure [BD10-BD1Z]	[48]
Chlorothiazide	DMLHESP	Moderate	Antagonize the effect of Sulindac when combined with Chlorothiazide.	Heart failure [BD10-BD1Z]	[47]
Furosemide	DMMQ8ZG	Moderate	Antagonize the effect of Sulindac when combined with Furosemide.	Heart failure [BD10-BD1Z]	[47]
Bumetanide	DMRV7H0	Moderate	Antagonize the effect of Sulindac when combined with Bumetanide.	Heart failure [BD10-BD1Z]	[47]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Sulindac and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[49]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Sulindac and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[50]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Sulindac and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[51]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Sulindac and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[31]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Sulindac and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[52]
Indapamide	DMGN1PW	Moderate	Antagonize the effect of Sulindac when combined with Indapamide.	Hypertension [BA00-BA04]	[47]
Trichlormethiazide	DMHAQCO	Moderate	Antagonize the effect of Sulindac when combined with Trichlormethiazide.	Hypertension [BA00-BA04]	[47]
Hydrochlorothiazide	DMUSZHD	Moderate	Antagonize the effect of Sulindac when combined with Hydrochlorothiazide.	Hypertension [BA00-BA04]	[53]
Dipyridamole	DMXY30O	Moderate	Increased risk of bleeding by the combination of Sulindac and Dipyridamole.	Hypertension [BA00-BA04]	[36]
Potassium chloride	DMMTAJC	Moderate	Increased risk of hyperkalemia by the combination of Sulindac and Potassium chloride.	Hypo-kalaemia [5C77]	[54]
Fludrocortisone	DMUDIR8	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Fludrocortisone.	Hypo-osmolality/hyponatraemia [5C72]	[30]
Balsalazide	DMO091F	Moderate	Increased risk of nephrotoxicity by the combination of Sulindac and Balsalazide.	Indeterminate colitis [DD72]	[29]
Ibandronate	DM0QZBN	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Ibandronate.	Low bone mass disorder [FB83]	[34]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Sulindac and Porfimer Sodium.	Lung cancer [2C25]	[55]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Sulindac and Idelalisib.	Mature B-cell leukaemia [2A82]	[56]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Sulindac and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[57]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Sulindac and Clofarabine.	Mature B-cell lymphoma [2A85]	[34]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Sulindac and Ibrutinib.	Mature B-cell lymphoma [2A85]	[58]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Sulindac and Ponatinib.	Mature B-cell lymphoma [2A85]	[59]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Sulindac and Exjade.	Mineral absorption/transport disorder [5C64]	[60]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Sulindac and Panobinostat.	Multiple myeloma [2A83]	[32]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Deflazacort.	Muscular dystrophy [8C70]	[30]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Sulindac and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[36]
Dasatinib	DMJV2EK	Major	Increased risk of bleeding by the combination of Sulindac and Dasatinib.	Myeloproliferative neoplasm [2A20]	[61]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Sulindac and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[62]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Sulindac and Prasugrel.	Myocardial infarction [BA41-BA43]	[34]
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Sulindac and Vorapaxar.	Myocardial infarction [BA41-BA43]	[63]
Tirofiban	DMQG17S	Moderate	Increased risk of bleeding by the combination of Sulindac and Tirofiban.	Myocardial infarction [BA41-BA43]	[64]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Sulindac and Sibutramine.	Obesity [5B80-5B81]	[42]
Dexfenfluramine	DMJ7YDS	Moderate	Increased risk of bleeding by the combination of Sulindac and Dexfenfluramine.	Obesity [5B80-5B81]	[42]
Polythiazide	DMCH80F	Moderate	Antagonize the effect of Sulindac when combined with Polythiazide.	Oedema [MG29]	[47]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Sulindac and MK-4827.	Ovarian cancer [2C73]	[34]
Aspirin	DM672AH	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Aspirin.	Pain [MG30-MG3Z]	[65]
Prednisone	DM2HG4X	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Prednisone.	Postoperative inflammation [1A00-CA43]	[30]
Hydrocortisone	DMGEMB7	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[30]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Sulindac and Epoprostenol.	Pulmonary hypertension [BB01]	[66]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Sulindac and Iloprost.	Pulmonary hypertension [BB01]	[66]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Sulindac and Everolimus.	Renal cell carcinoma [2C90]	[67]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Sulindac and Temsirolimus.	Renal cell carcinoma [2C90]	[67]
Gatifloxacin	DMSL679	Moderate	Additive CNS stimulant effects by the combination of Sulindac and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[37]
Methylprednisolone	DM4BDON	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[30]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Sulindac and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[34]
Prednisolone	DMQ8FR2	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Prednisolone.	Solid tumour/cancer [2A00-2F9Z]	[30]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Pitolisant.	Somnolence [MG42]	[34]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Sulindac and Naltrexone.	Substance abuse [6C40]	[68]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Sulindac and Apixaban.	Thrombosis [DB61-GB90]	[34]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Sulindac and Cangrelor.	Thrombosis [DB61-GB90]	[36]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Sulindac and Brilinta.	Thrombosis [DB61-GB90]	[34]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Sulindac and Cabozantinib.	Thyroid cancer [2D10]	[69]
Sirolimus	DMGW1ID	Major	Increased risk of nephrotoxicity by the combination of Sulindac and Sirolimus.	Transplant rejection [NE84]	[67]
Tacrolimus	DMZ7XNQ	Major	Increased risk of nephrotoxicity by the combination of Sulindac and Tacrolimus.	Transplant rejection [NE84]	[67]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Sulindac and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[33]
Chlorpropamide	DMPHZQE	Moderate	Increased risk of hypoglycemia by the combination of Sulindac and Chlorpropamide.	Type 2 diabetes mellitus [5A11]	[33]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Sulindac and Olsalazine.	Ulcerative colitis [DD71]	[29]
Cinoxacin	DM4EWNS	Moderate	Additive CNS stimulant effects by the combination of Sulindac and Cinoxacin.	Urinary tract infection [GC08]	[37]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Sulindac and Plazomicin.	Urinary tract infection [GC08]	[38]
Nalidixic acid	DMRM0JV	Moderate	Additive CNS stimulant effects by the combination of Sulindac and Nalidixic acid.	Urinary tract infection [GC08]	[37]
Triamcinolone	DM98IXF	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Sulindac and Triamcinolone.	Vasomotor/allergic rhinitis [CA08]	[30]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Sulindac and Betrixaban.	Venous thromboembolism [BD72]	[70]
-----------


⏷ Show the Full List of 113 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Sulindac 150 mg tablet	150 mg	Oral Tablet	Oral
Sulindac 200 mg tablet	200 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5425).
2	New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8.
10	Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors. Invest Ophthalmol Vis Sci. 1983 Oct;24(10):1426-9.
11	Fluo-cAMP is transported by multidrug resistance-associated protein isoform 4 in rat choroid plexus. J Neurochem. 2010 Oct;115(1):200-8.
12	Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
13	Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50.
14	ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
15	The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9.
16	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
17	Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
18	P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett. 2010 Dec;4(4):195-201.
19	Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009 Aug 13;114(7):1383-6.
20	Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J. 2002 Feb 1;361(Pt 3):497-503.
21	Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4.
22	Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001 Oct;24(10):1776-82.
23	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
24	Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5.
25	ClinicalTrials.gov (NCT02332005) 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN). U.S. National Institutes of Health.
26	Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors ... J Med Chem. 2005 May 5;48(9):3141-52.
27	A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005 Sep-Oct;19(5):247-53.
28	Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats. Eur J Pharmacol. 1991 Feb 7;193(2):185-91.
29	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
30	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
31	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
32	Cerner Multum, Inc. "Australian Product Information.".
33	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
34	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
35	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
36	Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
37	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
38	Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
39	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
40	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
41	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
42	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
43	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
44	Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
45	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
46	Canadian Pharmacists Association.
47	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
48	Abdel-Haq B, Magagna A, Favilla S, Salvetti A "Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects." J Cardiovasc Pharmacol 18 (1991): s33-6. [PMID: 1725198]
49	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
50	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
51	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
52	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
53	McCarthy JT, Torres VE, Romero JC, et al "Acute intrinsic renal failure induced by indomethacin." Mayo Clin Proc 57 (1982): 289-96. [PMID: 6952058]
54	Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
55	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
56	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
57	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
58	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
59	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
60	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
61	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
62	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
63	Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
64	Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
65	Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
66	Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
67	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
68	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
69	Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
70	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.